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Abstract
Objective—Mitomycin C (MMC) is used clinically to treat corneal scarring in human patients.
We investigated the safety and efficacy of MMC to treat corneal scarring in horses by examining
its effects at the early and late stages of disease using an in-vitro model.
Procedure—An in-vitro model of equine corneal fibroblast (ECF) developed was used. The
equine corneal fibroblast or myofibroblast cultures were produced by growing primary ECF in the
presence or absence of transforming growth factor beta-1 (TGFβ1) under serum-free conditions.
The MMC dose for the equine cornea was defined with dose-dependent trypan blue exclusion and
MTT [(3-4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays after applying MMC
to the cultures once for 2 minutes. The efficacy of MMC to control corneal scarring in horses was
determined by measuring mRNA and protein expression of corneal scarring markers (α-smooth
muscle actin and F-actin) with western blotting, immunocytochemistry and/or quantitative real-
time polymerase chain reactions.
Results—A single 2 minutes treatment of 0.02% or less MMC did not alter ECF phenotype,
viability, or cellular proliferation whereas 0.05% or higher MMC doses showed mild-to-moderate
cellular toxicity. The TGFβ1 at 1ng/ml showed significant myofibroblast formation in ECF under
serum-free conditions. A single 2 minute, 0.02% MMC treatment 24 hours (early) after TGFβ1
stimulation significantly reduced conversion of ECF to myofibroblasts, however, a single 0.02%
MMC treatment 11 days after TGFβ1 stimulation showed moderate myofibroblast inhibition.
Conclusions—That MMC safely and effectively reduced scarring in ECF by reducing the
degree of transdifferentiation of corneal fibroblasts to myofibroblasts in vitro. Further clinical in-
vivo investigations are warranted using MMC in horses.
Keywords
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INTRODUCTION
Scarring is a common ocular problem in horses, and may lead to significant visual deficits,
and even blindness. Many factors contribute to the frequency of corneal ulceration including
the size and anatomic location of the equine globe, as well as the environmental conditions
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to which they are exposed. Treatment of corneal ulceration can be costly, labor intensive,
and prolonged.1 Conventional treatment of corneal ulcers in horses utilizes topical and
systemic therapeutic agents such as antimicrobial/antifungal medications to control
infection, anti-collagenases to decrease stromal degradation, mydriatics for ciliary spasm
and stabilization of the blood-aqueous barrier, and non-steroidal anti-inflammatory drugs to
alleviate ocular pain.1–3 To the best of our knowledge, no agent specifically used to inhibit
equine corneal scarring has been investigated. The lack of a suitable experimental model has
been a major limitation to these investigations. Our laboratory recently defined parameters
for equine corneal keratocyte, fibroblast or myofibroblast cultures to study molecular
mechanisms associated with equine corneal wound healing; our goal is to test the therapeutic
potential of various agents effective for the treatment of equine corneal scarring. 4,5
Corneal wound healing is a complex physiological process and plays a critical role in the
maintenance of corneal structural integrity and clarity.6–9 It affects corneal epithelial cell
migration and proliferation, keratocyte apoptosis, extracellular matrix remodeling, and
transdifferentiation of keratocyte to fibroblasts and myofibroblasts.6,9 Numerous factors,
including growth factors, cytokines, and chemokines regulate this process.1,9 Transforming
Growth Factor β (TGFβ1) has been shown to play a key role in the conversion of equine
corneal fibroblasts (ECF) to myofibroblasts and thus the development of corneal scarring.
1,10 While the production of myofibroblasts is a normal component of this complex process,
the overproduction of myofibroblasts may be deleterious due to their adverse side-effect on
corneal transparency. Corneal stromal keratocytes produce and maintain the extracellular
matrix and actively participate in tissue repair. A change in the stromal environment alters
keratocyte function.1,9 Corneal scar formation is influenced by numerous cytokines and
results when myofibroblasts are overproduced.11–13 Myofibroblasts are contractile,
metabolically active, opaque cells containing intracellular microfilament bundles of F-actin
and alpha-smooth muscle actin (αSMA).14 Myofibroblasts are critical to normal corneal
wound healing.7,8 Once wound repair processes are complete, myofibroblast numbers are
believed to decrease via apoptosis, however the exact pathogenesis is still unknown.7,8
Multiple studies have shown that a decrease in myofibroblast production reduces corneal
fibrosis or haze.9,14–16
Currently, mitomycin C (MMC) is widely used clinically by physician ophthalmologists to
prevent corneal haze formation that can be a secondary complication after photorefractive
keratectomy and other refractive laser eye surgeries.10,17–20 Many physicians also advocate
its use for treating pterygium and conjunctival and corneal neoplasia.10 MMC is a powerful
alkylating agent with potent anti-tumor activity and has the ability to form a covalent
linkage with DNA to inhibit DNA, RNA, and protein synthesis.8,21 MMC has been found to
significantly inhibit proliferation of corneal epithelial, stromal and endothelial cells,
conjunctival fibroblasts and retinal pigment epithelial cells.9,10,22–25 Furthermore, MMC
demonstrated a significant decrease in corneal haze development by blocking corneal
fibroblast proliferation, a known mechanism resulting in corneal haze/scar.10,26–30
The purpose of our study was to examine the toxicity and anti-fibrotic effects of MMC on
cultured equine corneal fibroblast cells. Specifically, we investigated the safety and
therapeutic efficiency of MMC at an early time point (24 hours) and late time point (11
days) of myofibroblast or scar production in equine cornea using an in-vitro model of equine
corneal scarring. These two time points (24 hours and 11 days) were chosen to represent the
early and late stages of corneal scarring, respectively. Corneal scarring is initiated
immediately following corneal injury or infection, and cultures exposed to TGFβ1 for 24
hours represent this early stage of corneal scarring. In contrast, cultures exposed to TGFβ1
for 11 days mimic a later stage in corneal scarring.
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MATERIALS AND METHODS
Equine corneal fibroblast, keratocyte and myofibroblast cultures
Five full-thickness 6-mm axial corneal buttons were aseptically harvested from healthy
research horses undergoing humane euthanasia for reasons unrelated to this study. Slit-lamp
biomicroscopy was performed by a board-certified veterinary ophthalmologist (EAG) prior
to euthanasia to ensure that all samples were harvested from horses free of anterior segment
disease. Corneal buttons were washed with minimum essential medium (MEM; Gibco,
Invitrogen, Carlsbad, CA, USA) and the epithelium and endothelium was removed by gentle
scraping using a #10 Bard Parker scalpel blade (BD, Franklin Lakes, NJ, USA). Corneal
stroma was sub-sectioned and placed in tissue culture plates containing Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Invitrogen, Carlsbad, CA, USA) containing 10% fetal
bovine serum to obtain ECF. ECF were then incubated in a humidified CO2 incubator
(HERAcell, Thermo Scientific, USA) at 37°C. In approximately 3–10 days, fibroblasts
began migrating from the stromal sub-sections. Once the primary culture reached 90%
confluence, the stromal sub-sections were manually removed using rat-toothed forceps and
discarded. The confluent cells were trypsinized, cellular concentrations calculated using a
hemocytometer and re-plated on 60 mm tissue plates. Passages 1–3 of ECF were used for
this experiment. The monocultures of corneal keratocytes, fibroblasts and myofibroblasts
were selectively induced from the primary cultures generated from corneal explants by
altering media or cell seeding conditions. Specifically, a concentration of 50,000 cells per 60
mm plate in serum-free MEM provided equine corneal keratocyte cultures. Equine fibroblast
cultures were selectively produced by seeding 50,000 cells per 60 mm plate in MEM
medium supplemented with 10% fetal bovine serum. Myofibroblast cultures were induced
from seeding 10,000 fibroblasts per 60 mm plate in MEM medium supplemented with 10%
fetal bovine serum or serum-free MEM medium containing 1ng/ml TGFβ1.
Cytotoxicity studies
The cytotoxicity of MMC to ECF was evaluated using phase-contrast microscopy and
Trypan blue, MTT [(3-4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and
TUNEL assays. Microscopy was used to evaluate cellular morphological changes, Trypan
blue and MMT assays assessed cellular viability, and TUNEL assay detected apoptotic cells
in cultures at 24hours and 11days. Microscopy investigations utilized a phase-contrast
microscope (Leica DMIL) equipped with an imaging system (Leica DFC290). The ECF
cultures treated with MMC were examined at different time intervals and cell morphology
was recorded using digital photography.
Trypan blue assay was performed following manufacturer’s instructions. Briefly, at selected
time points, cells were trypsinised and mixed with equal amounts of 0.4% trypan blue
solution (Invitrogen, Carlsbad, CA, USA). Dead cells with ruptured membranes stained blue
and live cells white were counted with Neubauer’s chamber. Cellular viability was
calculated as a percent.
The MTT assay is colorimetric assay which utilizes a tetrazolium compound, MTT (Sigma-
Aldrich, St Louis, MO). The MTT is bio-reduced by viable cells to a purple color formazan
product which is detected at an absorbance of 570 nm by spectrophotometry. Ten μl of MTT
reagent was added the each well of 96-well plate containing 100 μl DMEM and 70%
confluent ECF cultures treated with or without MMC. Wells containing media alone without
cells served as negative controls. Plates were incubated at 37°C in a humidified 5% CO2
incubator and absorbance was recorded at 570 nm (BioTEk FLx 800, Winooski, VT, USA).
A fluorescence-based TUNEL assay was used to detect DNA fragmentation and apoptosis in
ECF. The MMC treated and untreated ECF cultures were fixed in acetone at −20°C for 2
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minutes, dried at room temperature for 5 minutes, and placed in PBS balanced salt solution.
Apoptosis was detected with ApopTag apoptosis detection kit (Millipore, Billerica, MA,
USA) following manufacturer’s instructions. Photographs were obtained using a fluorescent
microscope (Leica, Wetzlar, Germany) equipped with a digital camera (SpotCam RT KE,
Diagnostic Instruments Inc., Sterling Heights, MI, USA).
Immunocytochemistry and quantification of anti-fibrotic effect of MMC
Immunofluorescent staining for αSMA, a marker for myofibroblasts responsible for corneal
fibrosis, was performed using mouse monoclonal antibody for αSMA. The myofibroblast
formation in ECF was stimulated with TGFβ1.4 To evaluate anti-fibrotic effect of MMC,
0.02% MMC was added to cultures for 2 minutes once at 24 hours (early) after TGFβ1
stimulation or at 11 days (late) after TGFβ1 stimulation. A single 0.02% MMC treatment for
2 minutes demonstrated least toxicity to ECF. At study end-point (11days), cultures were
washed twice with PBS and incubated at room temperature with mouse monoclonal
antibody for F-actin (Invitrogen, Carlsbad, CA, USA) αSMA (DAKO, Carpinteria, CA,
USA) at a 1:200 dilution in 1X PBS for 90 minutes and with secondary antibody Alexa 488
or 594 goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) at a dilution of 1:500 for 1
hour. Cells were mounted with Vectashield containing DAPI (Vector Laboratories, Inc.,
Burlingame, CA, USA) to allow visualization of nuclei. Irrelevant isotype-matched primary
antibody, secondary antibody alone, and tissue sections from naïve eyes were used as
negative controls. Tissue culture plates were examined and photographed with Leica
fluorescent microscope (Leica, Wetzlar, Germany) equipped with a digital camera
(SpotCam RT KE, Diagnostic Instruments Inc., Sterling Heights, MI, USA) at the
conclusion of the study. The αSMA and DAPI-stained cells in ten randomly selected areas
were counted per 400X microscope field.
Immunoblotting
ECF were washed with ice-cold PBS and lysed in RIPA lysis buffer containing protease
inhibitor cocktail (Roche Applied Sciences, Indianpolis, IN, USA). The samples were
suspended in Laemmli’s denaturing sample buffer (30 μl) containing β-mercaptoethanol,
vortexed for 1 minute, centrifuged for 5 minutes at 10,000× g, and boiled at 70°C for 10
minutes. Protein samples were resolved by 4%–10%SDS–PAGE and transferred to a 0.45-
μm pore size PVDF membrane (Invitrogen, San Diego, CA). The membrane was incubated
with αSMA (DAKO, Carpinteria, CA, USA), fibronectin or GAPDH primary antibodies
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) followed by secondary anti-mouse-
or goat antibodies (Santa Cruz, Biotechnology Inc, Santa Cruz, CA, USA).
RNA extraction, cDNA synthesis and quantitative real-time PCR
The total RNA from ECF cultures (24hours and 11days) was extracted using RNeasy kit
(Qiagen Inc., Valencia, CA, USA) and reverse-transcribed to cDNA following
manufacturer’s instructions (Promega, Madison, WI, USA). Real-time PCR was performed
using iQ5 real-time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). A
50 μL’s reaction mixture containing 2 μL cDNA (250ng), 2 μL forward (200nM), 2 μL
reverse primer (200nM), and 25 μL 2X iQ SYBR green super mix (Bio-Rad Laboratories)
was run at universal cycle (95°C 3 min, 40 cycles of 95°C 30 sec followed by 60°C 60 sec)
following manufacturer’s instructions. For αSMA, forward primer sequence
TGGGTGACGAAGCACAGAGC and reverse primer sequence
CTTCAGGGGCAACACGAAGC were used. The house keeping gene beta actin forward
primer sequence was CGGCTACAGCTTCACCACCA and reverse primer sequence was
CGGGCAGCTCGTAGCTCTTC. The threshold cycle (CT) was used to detect the increase
in the signal associated with an exponential growth of PCR product during the log-linear
phase. The relative gene expression was calculated using the following formula: 2−ΔΔCT.
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The CT is a PCR cycle number at which the fluorescence meets the threshold in the
amplification plot and ΔCT is a subtraction product of target and housekeeping genes CT
values. The 2−ΔΔCT is a method for determining relative target mRNA quantity in samples.
The amplification efficiency for all used templates was validated by insuring that the
difference between linear slopes for all templates <0.1. Three independent reactions were
performed and the average (± SEM) results were calculated.
Image and statistical analysis
The results were expressed as mean ± standard error of the mean (SEM). Statistical analysis
was performed using two-way analysis of variance (ANOVA) followed by Bonferroni
multiple comparisons test for cell toxicity assay. The real-time PCR data results were
analyzed using one-way ANOVA followed by Tukey’s multiple comparison tests. A p-value
less than 0.05 was considered significant. The immunoblotting data was analyzed using
image J 1.38 X image analysis software (NIH, USA).
RESULTS
Cellular Viability
The experimental data collected from dose-dependent trypan blue and MTT assays
presented in Figures 1 and 2. A single 2 minute, 0.02% MMC treatment dose was the most
effective dose at reducing myofibroblast formation in ECF. One 0.02% MMC treatment to
ECF on day-1 (early) or day-11 (late) did not alter ECF cellular viability (Figure 1) or
phenotype (Figure 2). No statistically significant differences in the MMC treated or
untreated control groups were noted.
Apoptosis
The TUNEL assay detected increased apoptotic cell death in ECF cultures treated with
0.02% MMC early (Figure 3B) and late (Figure 3D) compared to untreated controls (Figure
3A and 3C).
F-actin immunocytochemistry
F-actin immunostaining of treatment groups was photographed (Figure 4). The ECF grown
in absence of TGFβ1 (normal fibroblasts) showed mild F-actin staining in microfilament
bundles (Figure 4A) whereas ECF grown in presence of TGFβ1 (myofibroblasts) showed
prominent intracellular staining of F-actin in large microfilaments bundles of contractile
apparatus (typical of myofibroblasts, Figure 4B). 4 A single 2 minute, 0.02% MMC
application to ECF in the early treatment group demonstrated a significant decrease in F-
actin staining, consistent with marked reduction in contractile apparatus formation (Figure
4C). However, the same MMC dose showed a moderate reduction in F-actin staining in late
treatment group (Figure 4D).
αSMA immunocytochemistry, quantification and western blotting
Immunocytochemistry of αSMA was performed on all experimental groups (Figure 5). No
αSMA was detected in ECF grown in absence of TGFβ1 (Figure 5A). By contrast, high
levels of αSMA were detected in ECF grown in presence of TGFβ1 (Figure 5B). One 2
minute application of 0.02% MMC to ECF on day-1 (early treatment group) showed
substantial inhibition of TGFβ1-induced transdifferentiation of ECF to myofibroblasts
(Figure 5C). However, similar MMC treatment performed on day-11 (late treatment group)
did not appear effective and showed only moderate inhibition of ECF to myofibroblasts
(Figure 5D).
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Quantification of αSMA immunocytochemical data is summarized in Figure 6. The ECF
grown under serum-free conditions in the presence of TGFβ1 (1ng/ml) showed significantly
high levels of αSMA staining (65–81%; p < 0.01) in the cells compared to control ECF
grown in the absence of TGFβ1 (<2%). One 2 minute 0.02% MMC application to ECF
significantly decreased TGFβ1-induced myofibroblast development in early (69% ± 5.8; p <
0.01) and late (28% ± 9.8) treatment groups (Figure 6).
Figure 7 demonstrates measurement of αSMA protein with western blot analysis. The
analysis of data after normalization further confirmed the anti-fibrotic effect of MMC on
ECF. The 0.02% MMC treatment to ECF grown in presence of TGFβ1 under serum-free
conditions effectively suppressed αSMA expression in both the early (≤ 65%) and late (≤
30%) treatment groups.
αSMA RNA quantification
Figure 8 shows quantification of αSMA RNA performed with real-time PCR. A statistically
significant 23-fold increase in αSMA RNA was detected in ECF exposed to TGFβ1 and no
change in ECF not exposed to TGFβ1 (Control). The early application of MMC
demonstrated a significant 14-fold reduction of αSMA RNA (p < 0.01).
DISCUSSION
Corneal scarring or fibrosis is a common sequela to corneal disease and frequently results in
vision deficits.1,3 Historically in veterinary ophthalmology, therapeutic efforts have been
focused on globe preservation and restoration of ocular comfort. Treatment options for
horses specifically geared towards prevention and/or the reduction of corneal fibrosis are
lacking. In-vitro studies represent a highly valuable tool to further our understanding of the
physiologic mechanisms of corneal wound healing. In-vitro models represent an ideal
controlled setting to test drug development with potentially clinically relevant applications.
Corneal fibrosis involves keratocyte apoptosis, proliferation and transdifferentiation of
fibroblasts into myofibroblasts.31,32 Smooth muscle actin expression and deposition of
extracellular matrix protein in a random pattern are primarily responsible for corneal fibrosis
and resultant visual opacity.7,32 Numerous studies in various animal models have
demonstrated the role of TGFβ1 in the development of corneal fibrosis.10,11,32–34
Additionally, it has been established that anti-TGFβ1 antibodies have reduced the
production of corneal haze in rabbits which had received photorefractive keratotomy (PRK).
35 Several reports have been published demonstrating the effectiveness of MMC to reduce
corneal fibrosis in rabbit, rodent and human corneas both in-vivo and in-vitro.10,29,30
Current literature reviews found only one report regarding the use of MMC on the equine
cornea. Rayner and Van found MMC effective for equine corneal squamous cell carcinoma
(0.4mg/ml MMC intraoperatively on the affected areas for 1 or 5 minutes).36 In that report,
no mention was made pertaining to the anti-fibrotic effects of MMC. To the best of our
knowledge this publication represents the first investigation of the anti-fibrotic effects of
MMC on equine cornea using an in-vitro model. Our data demonstrate the ability of MMC
to reduce myofibroblast production in ECF cultures and its effectiveness when applied at an
early or late stage of disease (e.g., reduction in the αSMA and F-actin levels; Figures 4–8).
Significant suppression of myofibroblast production was noted when MMC was applied at
an early stage of disease compared to a late stage consistent with the fact that the anti-
fibrotic effects of MMC are due to the inhibition of cellular proliferation and induction of
apoptosis.5–11 Although relatively more apoptosis was detected in the late MMC group
when compared to the early MMC group, the percent of apoptotic cells between the two
groups was not statistically significant. We believe that lack of statistical difference is due to
the higher ECF density in late treatment group (Figure 3C and 3D) compared to the early
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treatment group (Figure 3A and 3B) as evident from DAPI nuclear staining (Figure 3). The
late ECF treatment group received MMC on day-11 whereas the early ECF treatment group
received MMC on day-1. These findings are consistent with our in-vivo rabbit studies that
showed reduction in corneal scarring with MMC was due to increased apoptosis and
decreased cellular proliferation.10 Our data support previously published reports where
significant inhibition of corneal scarring in humans and rabbits in-vitro and in-vivo has been
demonstrated.8, 15–24 It is reasonable to expect that MMC may be useful clinically for the
reduction of corneal fibrosis in equine patients. MMC treatment in the face of an established
corneal scar may prove less beneficial compared to topical MMC application at the time of
corneal ulceration diagnosis or keratectomy; however, clinical trials are needed to further
assess the usefulness of its application in equine patients.
While the effectiveness of MMC against corneal haze is well-established in both rabbits and
humans, conflicting reports regarding its safety in human patients can be found.25–30
Several different protocols, involving different concentrations and exposure times, have
been suggested or used by clinicians to minimize unwanted side effects of MMC which
include increased stromal loss and corneal malacia as the result of increased cellular
toxicity.10,37,38 This pilot study addressed the safety of MMC for the equine cornea in an in-
vitro model by evaluating the response of MMC on ECF morphology and the proliferation
and cell death using various biochemical assays. In this study, the 0.02% dose of MMC was
deemed safe for the equine cornea because it did not induce significant apoptosis or alter
ECF proliferation or phenotype (Figures 1–3). MMC may prove beneficial in the reduction
of corneal fibrosis secondary to corneal injury in the equine patient and improve long-term
visual outcome. Further studies are warranted to determine optimal MMC dosing for
treatment of corneal fibrosis in the clinical patient.
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Figure 1.
Dose-dependent effect of early and late MMC treatment to ECF. Panels A and B show data
collected with trypan blue assay and panels C and D show MTT assay data. The doses of
MMC (0.02% or less) did not alter ECF viability whereas MMC doses higher than 0.02%
showed mild-to-moderate toxicity.
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Figure 2.
Phase-contrast light microscopy images of ECF. No morphological changes to ECF were
observed when 0.02% of MMC early (A) or late (B) treatment was performed, thus
establishing MMC safety to ECF in-vitro. Bar = 100μm
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Figure 3.
TUNEL assay detecting apoptosis induced by 0.02% MMC in ECF. Panel A demonstrates
the early control of no MMC treatment, panel B shows effects of early MMC treatment,
panel C is late control (no MMC) and panel D shows effects of late MMC treatment on
ECF. TUNEL-positive cells are stained in red and nuclei in blue with DAPI. Arrows denote
TUNEL-positive cells. Magnification 400x. Bar = 100μm
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Figure 4.
Immunocytochemical staining with phalloidin showing levels of F-actin in ECF control
group (A; no MMC treatment), in the presence of TGFβ1 (B), early MMC treatment group
(C) and late MMC treatment group (D). F-actin stained cells are red and nuclei are stained
blue with DAPI. Magnification 400x. Bar = 100μm
Buss et al. Page 13
Vet Ophthalmol. Author manuscript; available in PMC 2011 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
Immunocytochemical staining of α-SMA (green) showing anti-fibrotic effects of MMC on
ECF. The TGFβ1 untreated cultures did not show any α-SMA (A) while the TGFβ1 treated
cultures showed significant α-SMA staining (B). Early MMC treatment (C) showed
significant inhibition in TGFβ1-induced myofibroblast formation in ECF whereas late MMC
treatment showed moderate inhibition (D). The DAPI stained nuclei are shown in blue.
Magnification 400x. Bar = 100μm
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Figure 6.
Quantification of α-SMA-stained cells in ECF cultures treated with or without MMC.
Myofibroblast formation was significantly induced in the presence of TGFβ1. Early MMC
treatment significantly decreased TGFβ1-induced myofibroblast formation in ECF
compared to untreated controls, whereas late MMC treatment showed moderate reduction.
¬denotes p <0.01 (Con vs TGFβ1) and * represents p<0.01 (TGFβ1 vs TGFβ1+MMC).
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Figure 7.
Western blot analysis showing quantitative measurement of α-SMA (myofibroblast marker)
in ECF treated with or without TGFβ1 (1ng/ml) and 0.02% MMC. Equal quantity of protein
(50 μg) was loaded in each lane. GAPDH was used as house keeping gene. A single early
MMC treatment showed significant decrease in TGFβ1-induced myofibroblast formation in
ECF compared to untreated controls. The late MMC treatment showed moderate reduction
in α-SMA.
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Figure 8.
Quantitative real-time PCR reactions showing measurements of α-SMA in MMC treated or
untreated ECF. TGFβ1 exposure induced significant α-SMA formation in ECF and early
MMC treatment significantly decreased TGFβ1-induced myofibroblast formation in ECF.
Late MMC treatment showed moderate decrease in α-SMA RNA (data not shown).
¬indicates p <0.01 (Con vs TGFβ1) and * represents p<0.01 (TGFβ1 vs TGFβ1+MMC
early).
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